Compare PLETHICO PHARMA with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs JUBILANT LIFE SCIENCES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA JUBILANT LIFE SCIENCES PLETHICO PHARMA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x -1.1 15.2 - View Chart
P/BV x 0.0 1.8 0.9% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 PLETHICO PHARMA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
JUBILANT LIFE SCIENCES
Mar-19
PLETHICO PHARMA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs395898 44.0%   
Low Rs31618 5.1%   
Sales per share (Unadj.) Rs604.4572.0 105.7%  
Earnings per share (Unadj.) Rs32.536.2 89.7%  
Cash flow per share (Unadj.) Rs51.359.5 86.2%  
Dividends per share (Unadj.) Rs04.50 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs473.6301.9 156.8%  
Shares outstanding (eoy) m34.08159.28 21.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.41.3 26.6%   
Avg P/E ratio x6.620.9 31.4%  
P/CF ratio (eoy) x4.212.7 32.6%  
Price / Book Value ratio x0.52.5 17.9%  
Dividend payout %012.4 0.0%   
Avg Mkt Cap Rs m7,262120,694 6.0%   
No. of employees `000NA2.4 0.0%   
Total wages/salary Rs m1,59619,260 8.3%   
Avg. sales/employee Rs ThNM38,120.6-  
Avg. wages/employee Rs ThNM8,058.4-  
Avg. net profit/employee Rs ThNM2,414.3-  
INCOME DATA
Net Sales Rs m20,59891,108 22.6%  
Other income Rs m386357 108.1%   
Total revenues Rs m20,98491,466 22.9%   
Gross profit Rs m2,81817,390 16.2%  
Depreciation Rs m6423,709 17.3%   
Interest Rs m1,5932,198 72.5%   
Profit before tax Rs m96911,840 8.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,802 0.0%   
Tax Rs m-1383,268 -4.2%   
Profit after tax Rs m1,1075,770 19.2%  
Gross profit margin %13.719.1 71.7%  
Effective tax rate %-14.327.6 -51.8%   
Net profit margin %5.46.3 84.8%  
BALANCE SHEET DATA
Current assets Rs m18,87745,848 41.2%   
Current liabilities Rs m11,89620,897 56.9%   
Net working cap to sales %33.927.4 123.7%  
Current ratio x1.62.2 72.3%  
Inventory Days Days3657 63.3%  
Debtors Days Days19851 388.3%  
Net fixed assets Rs m9,86165,498 15.1%   
Share capital Rs m341159 213.9%   
"Free" reserves Rs m12,33147,930 25.7%   
Net worth Rs m16,13948,089 33.6%   
Long term debt Rs m4,70642,429 11.1%   
Total assets Rs m33,146114,685 28.9%  
Interest coverage x1.66.4 25.2%   
Debt to equity ratio x0.30.9 33.0%  
Sales to assets ratio x0.60.8 78.2%   
Return on assets %8.16.9 117.2%  
Return on equity %6.912.0 57.2%  
Return on capital %12.312.4 99.0%  
Exports to sales %21.40-   
Imports to sales %15.20-   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,136NA-   
Fx inflow Rs m4,40212,422 35.4%   
Fx outflow Rs m3,18417,227 18.5%   
Net fx Rs m1,219-4,805 -25.4%   
CASH FLOW
From Operations Rs m2,43711,215 21.7%  
From Investments Rs m-6,265-10,118 61.9%  
From Financial Activity Rs m2,4906,574 37.9%  
Net Cashflow Rs m-1,3377,612 -17.6%  

Share Holding

Indian Promoters % 82.7 45.6 181.4%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 4.3 8.7 49.4%  
FIIs % 5.5 21.2 25.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 21.1 35.5%  
Shareholders   10,665 23,815 44.8%  
Pledged promoter(s) holding % 85.7 15.9 540.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   SUVEN LIFESCIENCES  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  ORCHID PHARMA LTD  

Compare PLETHICO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY19); Net Profit Up 25.7% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 25.7% YoY). Sales on the other hand came in at Rs 24 bn (up 15.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA - FDC LTD. COMPARISON

COMPARE PLETHICO PHARMA WITH

MARKET STATS